Hi folks, what are your thoughts on where things stand with PYCAG5? In announcement on 21st Feb 2011, it said
"Phylogica said it was pursuing partnering opportunities for further development of lead candidate PYCAG5 and other neuro-protective Phylomers."
Here it is below:
Phylogica finds new potential for treating brain injury 12:23, Monday, 21 February 2011
Sydney - Monday - February 21: (RWE Aust Business News) -Phylogica (ASX:PYC), has successfully demonstrated pre-clinical proof of concept with a Phylomer peptide drug candidate for the treatment of traumatic brain injury. Using an internationally established pre-clinical model, a three-year collaborative study with the Australian Neuromuscular Research Institute and the University of Tasmania has shown the compound, known as PYCAG5, is able to protect neural tissue at lesion sites and significantly reduce inflammation. The peptide was identified using Phylogica's proprietary Phylomer drug discovery platform and the study was funded by the Neurotrauma Research Program (NRP) of the Western Australia Institute of Medical Research. Chief executive Paul Watt said he was particularly encouraged by these results, which could eventually pave the way for better outcomes in head injury patients around the world. "While several Phylomer peptides showed neuroprotective activity in this brain trauma model this particular peptide, PYCAG5, showed outcomes most consistent with therapeutic potential," he said. "This Phylomer significantly protected neural issue in the vicinity of the lesion at four days after the induced head injury and decreased the extent of inflammation, increasing the potential for healing at seven days post injury." Dr Watt indicated the average loss of neurons from the injured region treated with Phylomer PYCAG5 was less than a third of the average loss observed for mock-treated control animals, or animals treated with a non-Phylomer peptide. Phylogica is now pursuing partnering opportunities with major pharmaceutical and biotech companies for further development of its lead candidate, PYCAG5, and the company's other neuroprotective Phylomers. ENDS
Then... May 25/2011
PHYLOGICA REPORTS PROMISING DATA ON CELL-PENETRATING PHYLOMER® PEPTIDES PERTH, AUSTRALIA: May 25, 2011 –
Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today promising validation of its novel cell-penetrating Phylomer peptides. The findings were presented for the first time by Phylogica’s CEO, Dr. Paul Watt, at the TIDES Conference on Peptide Discovery and Development, being held in Boston, MA, on 22-25 May 2011. The theme of this event was ‘Peptides Coming of Age as Intracellular Drugs, Delivery Agents and Modulators of Previously Undruggable Targets and Disease Mechanisms’.
“We have identified several distinct structural families of cell-penetrating Phylomers that have shown encouraging activity, A number of these peptides come from completely new structural families, bearing no resemblance to previously identified cell-penetrating peptides”, commented Dr. Watt. “These important data underscore the opportunity for Phylomers to target disease mechanisms that have traditionally not been accessible for drug discovery and they also reaffirm our technology as a rich source from which to discover new peptide classes.”
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)